• info@heparegenix.com
  • +49 (0)7071 7912810
  • Sitemap
  • Site Notice
  • Privacy Policy

HepaRegeniX GmbH

  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • Press
  • Contact
Search
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • Press
  • Contact

HepaRegeniX GmbH: Keyvisual and unique therapeutic concept HepaRegenix develops a new for the treatment of liver diseases. Find out more
Homep3889712020-11-30T13:35:34+01:00

Latest Press Releases

HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model

p3889712020-12-03T10:27:14+01:00

New preclinical data indicate beneficial therapeutic effects in non-alcoholic steatohepatitis (NASH)-associated liver carcinomas.

12/03/2020
By p3889712020, Press releaseComments Off
Read more...
More Press Releases
Get In Touch
HepaRegeniX GmbH: Logo

HepaRegeniX has successfully discovered and developed several preclinical drug candidates for the treatment of acute and chronic liver diseases.

Get in touch

Phone: +49 (0)7071 7912810
Fax: +49 (0)7071 7912809
E-mail: info@heparegenix.com

Address

HepaRegeniX GmbH
Eisenbahnstraße 63
72072 Tübingen
Germany

© Copyright 2016-2020 HepaRegeniX GmbH. All Rights Reserved.